The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis

British Journal of Pharmacology

Volumn 169, Issue 1, 2013, Pages 213-229

  Romano, B ^a,b   Borrelli, F ^a,b   Fasolino, I ^a,b   Capasso, R ^a,b   Piscitelli, F ^b   Cascio, M G ^c   Pertwee, R G ^c   Coppola, D ^d   Vassallo, L ^d   Orlando, P ^b,e   Di Marzo, V ^b   Izzo, A A ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d Unit of Cardiology Ospedale dei Pellegrini   (Italy)

^e INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

Author keywords

cannabichromene; cannabinoid receptors; endocannabinoids; inflammatory bowel disease; macrophages; nitric oxide; non psychotropic cannabinoids; oleoylethanolamide; transient receptor potential (TRP) channels; TRPA1

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABICHROMENE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CARVACROL; CINNAMALDEHYDE; CYCLOOXYGENASE 2; DINITROBENZENE SULPHONIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; MYELOPEROXIDASE; N OLEOYLETHANOLAMINE; NITRIC OXIDE; NITROBENZENE DERIVATIVE; PALMIDROL; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZENESULFONATES; BLOTTING, WESTERN; CANNABINOIDS; CHROMATOGRAPHY, LIQUID; COLITIS; DOWN-REGULATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED ICR; NITRIC OXIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSIENT RECEPTOR POTENTIAL CHANNELS; UP-REGULATION;

EID: 84876268807     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12120     Document Type: Article

References (64)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164: S1-S324.
2. Alhouayek M, Muccioli GG, (2012). The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med 18: 615-625.
3. Aviello G, Rowland I, Gill CI, Acquaviva AM, Capasso F, McCann M, et al. (2010). Anti-proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco-2 human adenocarcinoma cells. J Cell Mol Med 14: 2006-2014.
4. Aviello G, Borrelli F, Guida F, Romano B, Lewellyn K, De Chiaro M, et al. (2011). Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo. J Mol Med (Berl) 89: 891-902.
5. Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, et al. (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 90: 925-934.
6. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS, (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45: 50-52.
7. Booz GW, (2011). Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 51: 1054-1061.
8. Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, et al. (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med (Berl) 87: 1111-1121.
9. Brightbill HD, Plevy SE, Modlin RL, Smale ST, (2000). A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J Immunol 164: 1940-1951.
10. Brizzi A, Brizzi V, Cascio MG, Bisogno T, Siriani R, Di Marzo V, (2005). Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. J Med Chem 48: 7343-7350.
11. Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, et al. (2010). Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 31: 1584-1591.
12. Burstein SH, Zurier RB, (2009). Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 11: 109-119.
13. Cao S, Liu J, Song L, Ma X, (2005). The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. J Immunol 74: 3484-3492.
14. Capasso R, Aviello G, Romano B, Borrelli F, De Petrocellis L, Di Marzo V, et al. (2012). Modulation of mouse gastrointestinal motility by allyl isothiocyanate, a constituent of cruciferous vegetables (Brassicaceae): evidence for TRPA1-independent effects. Br J Pharmacol 165: 1966-1977.
15. Cox ML, Welch SP, (2004). The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat. Eur J Pharmacol 16: 65-74.
16. Croci T, Landi M, Galzin AM, Marini P, (2003). Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140: 115-122.
17. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V, (2006). Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20: 568-570.
18. De Petrocellis L, Vellani V, Schiano-Moriello A, Marini P, Magherini PC, Orlando P, et al. (2008). Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther 325: 1007-1015.
19. De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 1479-1494.
20. De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, et al. (2012). Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) 204: 255-266.
21. DeLong GT, Wolf CE, Poklis A, Lichtman AH, (2010). Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. Drug Alcohol Depend 112: 126-133.
22. Di Marzo V, Izzo AA, (2006). Endocannabinoid overactivity and intestinal inflammation. Gut 55: 1373-1376.
23. Di Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F, et al. (2008). The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 153: 1272-1280.
24. Engel MA, Leffler A, Niedermirtl F, Babes A, Zimmermann K, Filipovic̈ MR, et al. (2011). TRPA1 and substance P mediate colitis in mice. Gastroenterology 141: 1346-1358.
25. Goldblum SE, Wu KM, Jay M, (1985). Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 59: 1978-1985.
26. Grimaldi P, Orlando P, Di Siena S, Lolicato F, Petrosino S, Bisogno T, et al. (2009). The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A 106: 11131-11136.
27. Hawiger J, (2001). Innate immunity and inflammation: a transcriptional paradigm. Immunol Res 23: 99-109.
28. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB, (1997). Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69: 631-638.
29. Holley JH, Hadley KW, Turner CE, (1975). Constituents of Cannabis sativa L. XI: cannabidiol and cannabichromene in samples of known geographical origin. J Pharm Sci 64: 892-894.
30. Holzer P, (2011). Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol Ther 131: 142-170.
31. Huestis MA, (2005). Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 168: 657-690.
32. Ippoushi K, Itou H, Azuma K, Higashio H, (2002). Effect of naturally occurring organosulfur compounds on nitric oxide production in lipopolysaccharide-activated macrophages. Life Sci 71: 411-419.
33. Izzo AA, Camilleri M, (2009). Cannabinoids in intestinal inflammation and cancer. Pharmacol Res 60: 117-125.
34. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
35. Izzo AA, Capasso R, Aviello G, Borrelli F, Romano B, Piscitelli F, et al. (2012). Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol 166: 1444-1460.
36. Jamontt JM, Molleman A, Pertwee RG, Parsons ME, (2010). The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 160: 712-723.
37. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
38. Krawisz JE, Sharon P, Stenson WF, (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87: 1344-1350.
39. Lahat A, Lang A, Ben-Horin S, (2012). Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion 85: 1-8.
40. Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, et al. (2011). Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 23: 891-896.
41. Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, et al. (2006). New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br J Pharmacol 147: 83-91.
42. Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Tellez C, Williams S, et al. (2003). Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res 63: 3632-3636.
43. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
44. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
45. McMahon SB, Wood JN, (2006). Increasingly irritable and close to tears: TRPA1 in inflammatory pain. Cell 124: 1123-1125.
46. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, et al. (2011). Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol 162: 584-596.
47. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, et al. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 15: 9561-9566.
48. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, et al. (2004). The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209.
49. 9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 55: 1209-1217.
50. Moncada S, Palmer RM, Higgs EA, (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
51. Moore KW, de Waal MR, Coffman RL, O'Garra A, (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
52. Moran MM, McAlexander MA, Bírõ T, Szallasi A, (2011). Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov 10: 601-620.
53. Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM, (2011). Treatment of Crohn's disease with cannabis: an observational study. Isr Med Assoc J 13: 455-582.
54. Osanai M, Nishikiori N, Murata M, Chiba H, Kojima T, Sawada N, (2007). Cellular retinoic acid bioavailability determines epithelial integrity: role of retinoic acid receptor alpha agonists in colitis. Mol Pharmacol 71: 250-258.
55. Ross RA, Brockie HC, Pertwee RG, (2000). Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol 401: 121-130.
56. Russo EB, (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344-1364.
57. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. (2001). Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410: 471-475.
58. Schicho R, Storr M, (2012). Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice. Pharmacology 89: 149-155.
59. Sofia RD, Nalepa SD, Vassar HB, Knobloch LC, (1974). Comparative anti-phlogistic activity of delta 9-tetrahydrocannabinol, hydrocortisone and aspirin in various rat paw edema models. Life Sci 15: 251-260.
60. Tubaro A, Giangaspero A, Sosa S, Negri R, Grassi G, Casano S, et al. (2010). Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins. Fitoterapia 81: 816-819.
61. Turner CE, Elsohly MA, (1981). Biological activity of cannabichromene, its homologs and isomers. J Clin Pharmacol 21: 283S-291S.
62. Wirth PW, Watson ES, ElSohly M, Turner CE, Murphy JC, (1980). Anti-inflammatory properties of cannabichromene. Life Sci 26: 1991-1995.
63. Yoshino T, Nakase H, Honzawa Y, Matsumura K, Yamamoto S, Takeda Y, et al. (2010). Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis 16: 2022-2033.
64. Zurier RB, (2003). Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 88: 462-466.